AGP Picks
View all

The best news from Yemen on health and wellness

Provided by AGP

Yemen Health Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Yemen Health Report.

Press releases published on May 15, 2026

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
Sienna Announces May Dividend
SRx Health Solutions Announces Board Approval to Dividend 75% of Profits from Investment in Astro Investment XVII, an Affiliate of Astro Capital and SPV with Investments in SpaceX and Other Artificial Intelligence and Space Companies
CytoDyn to Present at the LD Micro Invitational XVI
  Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting
Research Highlights Diet and Hormone Therapy Advances in Preventing Recurrent UTIs in Women
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
LifeMD to Participate in Upcoming Investor Conferences

Share us

on your social networks:

Sign up for:

Yemen Health Report

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.